Skip to Content Facebook Feature Image

Usain Bolt on his track greatness: "I wanted to set high standards and I did"

News

Usain Bolt on his track greatness: "I wanted to set high standards and I did"
News

News

Usain Bolt on his track greatness: "I wanted to set high standards and I did"

2025-09-15 13:57 Last Updated At:14:10

TOKYO (AP) — On the night track turned to Jamaica once again to find the World's Fastest Man, the greatest Jamaican sprinter was in a sky box in the stadium — his presence literally hovering over a sport that hasn't been the same since he left.

Oblique Seville might be the new 100-meter world champion. Usain Bolt remains the only track star of this century whose fame cascades well beyond sports.

Eight years since his retirement, nobody has come close to matching his times or his presence. In an interview before Sunday night's races at the track worlds, he said he feels great about that, because "that's what I worked for.”

“When I was competing, I was working to break the benchmark,” he said. “Now that I've retired, it's a great feeling to know that I'm the benchmark if you want to be the best, you want to be a legend. I wanted to set high standards and I did. I'm happy about that.”

The numbers tell part of this story: Eight Olympic gold medals. Eleven gold medals at world championships. Three world records — 9.58 seconds in the 100, 19.19 in the 200 and 36.84 in the 4x100 relay — that still stand.

No runner has come within .12 seconds of either of his individual marks since he retired.

Asked why that is, despite a world in which shoe and track technology gives runners a bigger boost than 15 years ago when he was in his prime, Bolt offered a window into why he remains his sport's most engaging ambassador.

“Do you really want the answer? We're just more talented,” he said. “You look at it. I'm just saying, you can't run faster (just) with brand-new spikes.”

Speed, though, is only part of Bolt's story. It was his ability to use the platform to entertain and bring people together — a skill that couldn't be overlooked in an era when the Olympics needed a recharge — that made Bolt one of track's most important characters.

From his trademark bow-and-arrow pose to his leisurely victory laps around the track with the reggae music blaring — from his mile-wide smile to the joy he so effortlessly exuded despite the excruciating nature of his work — he elevated the sport into a personality-driven lovefest and gave people a reason to watch.

“It's the personality," he said. "I think a lot of people, they try to be fun but it comes off different. It's just having a good time. If you try too hard, it's not going to be the same. But I was just having a good time. That's how I looked at it. I tried to engage with fans and that's why they gravitated to it.”

Sunday marked Bolt's first appearance at an Olympics or worlds since he exited the sport after the 2017 championships in London.

He is now the father of a 5-year-old daughter, Olympia Lightning Bolt, and 4-year-old twin sons, Saint Leo and Thunder Bolt. To them, Bolt is just Dad. But the greatest sprinter of all time said their view might change at the next world championships — two years from now in the place where his career lifted off like a rocket: Beijing.

“I'm excited because I get to bring my kids and I can tell them, ‘Listen, this is where it all happened,’" he said of the 2008 Olympics where he set three world records and won three gold medals. “I've shown my kids videos and stuff like that. They'll be 6 and 7, and they'll kind of understand the moment, and I can explain to them what their dad has done over the years.”

FILE - Jamaica's Usain Bolt crosses the finish line to win gold in the men's 100-meter final during the athletics in the Olympic Stadium at the 2012 Summer Olympics, London, Sunday, Aug. 5, 2012. (AP Photo/David J. Phillip, File)

FILE - Jamaica's Usain Bolt crosses the finish line to win gold in the men's 100-meter final during the athletics in the Olympic Stadium at the 2012 Summer Olympics, London, Sunday, Aug. 5, 2012. (AP Photo/David J. Phillip, File)

FILE - Jamaica's Usain Bolt celebrates as he wins the men's 200-meter final with a world record during the athletics competitions in the National Stadium at the Beijing 2008 Olympics in Beijing, Wednesday, Aug. 20, 2008. (AP Photo/Thomas Kienzle, File)

FILE - Jamaica's Usain Bolt celebrates as he wins the men's 200-meter final with a world record during the athletics competitions in the National Stadium at the Beijing 2008 Olympics in Beijing, Wednesday, Aug. 20, 2008. (AP Photo/Thomas Kienzle, File)

FILE - Usain Bolt from Jamaica celebrates winning the gold medal in the men's 200-meter final during the athletics competitions of the 2016 Summer Olympics at the Olympic stadium in Rio de Janeiro, Brazil, Thursday, Aug. 18, 2016. (AP Photo/David J. Phillip, File)

FILE - Usain Bolt from Jamaica celebrates winning the gold medal in the men's 200-meter final during the athletics competitions of the 2016 Summer Olympics at the Olympic stadium in Rio de Janeiro, Brazil, Thursday, Aug. 18, 2016. (AP Photo/David J. Phillip, File)

NEWARK, Del.--(BUSINESS WIRE)--Jan 15, 2026--

QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalysis and clinical trials announces the successful implementation of Oracle Argus, a premier pharmacovigilance system designed to support comprehensive safety case management for clinical trials.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115711485/en/

The adoption of the Oracle Argus drug safety platform underscores QPS’s commitment to advancing patient safety, regulatory compliance, and operational excellence across its clients’ clinical drug development programs. Integrating this industry-standard safety platform strengthens QPS’ ability to capture, manage, and report adverse events in accordance with global regulatory requirements.

“Ensuring patient safety and data integrity is at the heart of what we do when conducting clinical trials,” said Derek Grimes, Executive Vice President of QPS. “Oracle Argus provides us with a robust, scalable solution to support the growing needs of our customer’s clinical trial portfolios and the evolving expectations of regulatory authorities worldwide.”

“Oracle Argus provides QPS Holdings, LLC with a trusted, globally recognized drug safety platform that supports compliance with stringent pharmacovigilance standards and regulations, while streamlining end-to-end safety operations and insights at scale,” said Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences. “With our industry-leading solutions, QPS Holdings, LLC can further transform and elevate its safety case management for customers worldwide.”

The deployment of Oracle Argus will enable QPS to:

As the demand for innovative therapies continues to rise, CROs play a critical role in managing both development speed and patient safety. By leveraging the Oracle Argus platform, QPS is well-positioned to deliver on its mission to accelerate pharmaceutical breakthroughs across the globe by delivering custom-built research services.

###

ABOUT QPS HOLDINGS, LLC

QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, bioanalysis, preclinical and clinical drug development services. Since 1995, QPS has grown from a small bioanalysis shop into a full-service CRO with 1,200+ employees in the US, Europe, Asia and India. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, PBMC processing, central safety labs, clinical trials, and clinical research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, turnkey laboratories, Phase I/II clinical units, and multi-site clinical research services. For more information, visit http://www.qps.com or email info@qps.com.

ABOUT ORACLE ARGUS

Oracle Argus is an industry-leading, trusted solution for processing, analyzing, and reporting adverse event cases originating in pre-market and post-market drugs, biologics, vaccines, devices, and combination products. Oracle has been a Leader in the IDC MarketScape: Worldwide Life Science R&D Pharmacovigilance Technology Solutions and Consulting Services 2025 Vendor Assessment (doc # US53669225, July 2025). To learn more about Oracle’s pharmacovigilance portfolio visit: https://www.oracle.com/life-sciences/safety-solutions/argus-safety-case-management/. Trademarks: Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation.

Derek Grimes, EVP, Global Head of Clinical Research at QPS Holdings, LLC.

Derek Grimes, EVP, Global Head of Clinical Research at QPS Holdings, LLC.

Recommended Articles